In metformin-treated patients with type 2 diabetes, exenatide reduced HbA1c more than sitagliptin.
In plain wordsIn patients with diabetes taking metformin, exenatide reduced HbA1c more than sitagliptin.
- Peptide
- Exenatide (exendin-4)
- Outcome
- DecreaseHbA1c versus sitagliptin
- Study
n = 326
- Comparator
- Sitagliptin
- Analysis
- Primary
- Outcome group
- Glycemic control · Metabolic and weight
- Studied dose
- 2 mg once weekly · injection · 26 weeksAs given in this study (human).
Measurements
- HbA1c change
- −1.5%
- exenatide
- HbA1c change
- −0.9%
- sitagliptin
- HbA1c treatment difference
- −0.6%
- exenatide versus sitagliptin
Source sentences
Treatment differences were -0.6% (95% CI -0.9 to -0.4, p<0.0001) for exenatide versus sitagliptin, and -0.3% (-0.6 to -0.1, p=0.0165) for exenatide versus pioglitazone.
5 context sentences(design, population, supporting numbers)
Treatment with exenatide reduced HbA(1c) (least square mean -1.5%, 95% CI -1.7 to -1.4) significantly more than did sitagliptin (-0.9%, -1.1 to -0.7) or pioglitazone (-1.2%, -1.4 to -1.0).
Primary endpoint was change in HbA(1c) between baseline and week 26.
491 patients received at least one dose of study drug and were included in the intention-to-treat analysis (160 on exenatide, 166 on sitagliptin, and 165 on pioglitazone).
In this 26-week randomised, double-blind, double-dummy, superiority trial, patients with type 2 diabetes who had been treated with metformin, and at baseline had mean glycosylated haemoglobin (HbA(1c)) of 8.5% (SD 1.1), fasting plasma glucose of 9.1 mmol/L (2.6), and weight of 88.0 kg (20.1), were e…
Patients were randomly assigned to receive: 2 mg injected exenatide once weekly plus oral placebo once daily; 100 mg oral sitagliptin once daily plus injected placebo once weekly; or 45 mg oral pioglitazone once daily plus injected placebo once weekly.